| P2093 | author name string | Fang Li | |
| | Yongqian Shu | |
| | Di Wu | |
| | Kejun Nan | |
| | Min Tao | |
| | Aiping Lu | |
| | Xiubao Ren | |
| | Yiping Zhang | |
| | Baocheng Wang | |
| | Shukui Qin | |
| | Houjie Liang | |
| | Jun Guo | |
| | Junling Li | |
| | Tongyu Lin | |
| | Xiaohui Niu | |
| | Jun Liang | |
| | Xin Song | |
| | Chuanliang Cui | |
| | Lu Si | |
| | Zhihong Chi | |
| | Hongming Pan | |
| | Xiaolin Xu | |
| | Xiaohong Chen | |
| | Wenbin Wei | |
| | Xiaoshi Zhang | |
| | Junyi Zhang | |
| | Jiwei Liu | |
| | Nan Du | |
| | Yun Fan | |
| | Huiyan Zhu | |
| | Man Lu | |
| | Lingying Wu | |
| | Aiwen Wu | |
| | Guoxin Ren | |
| | Kangsheng Gu | |
| | Yongheng Li | |
| P2860 | cites work | The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up | Q79890286 |
| | Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors | Q79899321 |
| | Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma | Q79947173 |
| | Identification of high-risk patients among those diagnosed with thin cutaneous melanomas | Q79975637 |
| | Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation | Q80263164 |
| | Phase II trial of weekly paclitaxel in patients with advanced melanoma | Q81251337 |
| | Mutation of the p16/CDKN2 gene and loss of heterozygosity in malignant mucosal melanoma and adenoid cystic carcinoma of the head and neck | Q81388196 |
| | Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26 | Q81606793 |
| | [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study] | Q81797318 |
| | Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma | Q81936078 |
| | Importance of clear resection margins in anorectal malignant melanoma | Q82257147 |
| | Results of sentinel lymph node biopsy in patients with thin melanoma | Q82584808 |
| | Copy number variations and clinical outcome in atypical spitz tumors | Q83288549 |
| | Predictors of positive sentinel lymph node in thin melanoma | Q83514090 |
| | A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients | Q83863771 |
| | Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy | Q83908819 |
| | First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07) | Q83992836 |
| | Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial | Q24530611 |
| | Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 |
| | Mutations in GNA11 in uveal melanoma | Q24625723 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 |
| | Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi | Q24646052 |
| | The clinical features and optimal treatment of anorectal malignant melanoma | Q26828599 |
| | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review | Q26830033 |
| | Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification | Q27851656 |
| | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial | Q27853021 |
| | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities | Q28204383 |
| | Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 |
| | Prognostic implications of monosomy 3 in uveal melanoma | Q28277919 |
| | Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death | Q28288495 |
| | Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma | Q28378420 |
| | Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma | Q28543960 |
| | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 |
| | Final version of 2009 AJCC melanoma staging and classification | Q29614803 |
| | Distinct sets of genetic alterations in melanoma | Q29614965 |
| | High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 |
| | Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 |
| | Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 |
| | Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 |
| | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 |
| | Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 |
| | Vulvar Melanoma: A Retrospective Analysis and Literature Review | Q30308344 |
| | Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). | Q30384829 |
| | Anal melanoma | Q30437650 |
| | Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor | Q36929804 |
| | A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma | Q36984477 |
| | Genetic mutations involved in melanoma: a summary of our current understanding | Q37045209 |
| | Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management | Q37060742 |
| | Sinonasal melanoma: a clinicopathologic review of 61 cases | Q37099296 |
| | Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines | Q37129949 |
| | Recent approaches to improve the antitumor efficacy of temozolomide. | Q37370405 |
| | Diagnosis and treatment of melanoma brain metastasis: a literature review | Q37531863 |
| | Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. | Q37660804 |
| | Outcome of sinonasal melanoma: clinical experience and review of the literature | Q37690271 |
| | Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. | Q37697383 |
| | Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study | Q37822609 |
| | Treatment and outcomes of anorectal melanoma | Q37825002 |
| | AJCC melanoma staging update: impact on dermatopathology practice and patient management | Q37850827 |
| | Mucosal melanoma of the head and neck: predictors of prognosis | Q37866566 |
| | Lentigo Maligna: Melanoma In Situ on Chronically Sun-Damaged Skin | Q37898119 |
| | Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review | Q38033002 |
| | Mucosal melanoma of the head and neck: 32-year experience in a tertiary referral hospital | Q38060660 |
| | Radiation Therapy for Mucosal Melanoma of the Head and Neck | Q38096789 |
| | Anorectal Malignant Melanoma: Extensive 45-Year Review and Proposal for a Novel Staging Classification | Q38108649 |
| | Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma | Q38159945 |
| | Head and neck mucosal melanoma: a review | Q38178433 |
| | Update on primary mucosal melanoma. | Q38210789 |
| | Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review | Q38239550 |
| | Investigating the role of melanin in UVA/UVB- and hydrogen peroxide-induced cellular and mitochondrial ROS production and mitochondrial DNA damage in human melanoma cells | Q39426359 |
| | Epidemiologic aspects of uveal melanoma | Q39632521 |
| | A single-institution validation of the AJCC staging system for stage IV melanoma | Q40094305 |
| | International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma | Q41630935 |
| | Cytogenetic characterization of tumors of the vulva and vagina | Q42446612 |
| | A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma | Q43106634 |
| | The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death | Q43286776 |
| | Epidemiology and prognosis of anorectal melanoma | Q43694744 |
| | Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma | Q43842013 |
| | Tumour regression does not increase the risk of sentinel node involvement in thin melanomas | Q44353499 |
| | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 |
| | Management of vulvar melanoma | Q44517049 |
| | 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. | Q44543762 |
| | Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma | Q44932116 |
| | Fraction size in external beam radiation therapy in the treatment of melanoma | Q45031579 |
| | Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma | Q45036059 |
| | Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group | Q74463785 |
| | Guidelines of care for primary cutaneous melanoma | Q74544679 |
| | Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique | Q74601046 |
| | Primary mucosal malignant melanoma of the head and neck | Q77759737 |
| | Acral lentiginous melanoma | Q77761855 |
| | BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 |
| | The prognostic importance of sentinel lymph node biopsy in thin melanoma | Q79761878 |
| | Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy | Q79838122 |
| | Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma | Q79843514 |
| | [Prognosis after sentinel node biopsy in malignant melanoma] | Q79848521 |
| | The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society | Q31995716 |
| | Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial | Q33224408 |
| | Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group | Q33372613 |
| | Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma | Q33384029 |
| | Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study | Q33567330 |
| | Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? | Q33604057 |
| | Positive iliac and obturator nodes in melanoma: survival and prognostic factors | Q33642969 |
| | Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? | Q33642975 |
| | A molecular revolution in uveal melanoma: implications for patient care and targeted therapy | Q33717375 |
| | Final trial report of sentinel-node biopsy versus nodal observation in melanoma | Q33760173 |
| | Ipilimumab for patients with advanced mucosal melanoma | Q33777469 |
| | Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases | Q33829284 |
| | A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775 | Q33871014 |
| | Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria | Q33881765 |
| | High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. | Q33905836 |
| | Management options and survival in malignant melanoma of the sinonasal mucosa | Q33965635 |
| | Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system | Q34086787 |
| | Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline | Q34127695 |
| | Therapeutic implications of the emerging molecular biology of uveal melanoma. | Q34173920 |
| | Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology | Q34210955 |
| | Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese | Q34287626 |
| | Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases | Q34315676 |
| | Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 |
| | Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis | Q34498776 |
| | High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 |
| | Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas | Q34514256 |
| | Excision margins in high-risk malignant melanoma | Q34545721 |
| | Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model | Q34545994 |
| | Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. | Q34557221 |
| | Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma | Q34563261 |
| | Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 |
| | Sentinel-node biopsy or nodal observation in melanoma | Q34571347 |
| | The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma | Q34573029 |
| | Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? | Q34573039 |
| | Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial | Q34594112 |
| | Role of sentinel lymph node biopsy in patients with thin melanoma | Q34607033 |
| | A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. | Q34608282 |
| | The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma | Q34611113 |
| | Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities | Q34616174 |
| | Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma | Q34648335 |
| | Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma | Q34656538 |
| | Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. | Q34660516 |
| | Genomic Classification of Cutaneous Melanoma | Q34670776 |
| | Taxol in malignant melanoma. | Q34724520 |
| | Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr | Q34747181 |
| | Surgical techniques of melanoma and sentinel node biopsy | Q34778792 |
| | Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database | Q35023404 |
| | A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. | Q35050558 |
| | Surgical therapy for anorectal melanoma | Q35069381 |
| | Incidence of uveal melanoma in the United States: 1973-1997. | Q35128733 |
| | Ocular melanoma: a review and the relationship to cutaneous melanoma | Q35202353 |
| | Systematic review of medical treatment in melanoma: current status and future prospects. | Q35584299 |
| | Primary malignant melanoma of the vulva--an aggressive tumor for modeling the genesis of non-UV light-associated melanomas | Q35883874 |
| | Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma | Q36102856 |
| | Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma | Q36113448 |
| | Vulvar melanoma: review of diagnosis, staging, and therapy | Q36116819 |
| | Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | Q36117266 |
| | BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. | Q36346020 |
| | Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma | Q36426516 |
| | Pathology of melanoma | Q36445925 |
| | Sentinel node mapping for melanoma: results of trials and current applications | Q36750546 |
| | Primary mucosal melanoma | Q36756223 |
| | Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis | Q36795247 |
| | Frequency and Duration of Remission After Isolated Limb Perfusion for Melanoma | Q36878183 |
| | Importance of sentinel lymph node biopsy in patients with thin melanoma | Q36923881 |
| | Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma | Q45172068 |
| | Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma | Q45300701 |
| | Biochemotherapy in patients with advanced head and neck mucosal melanoma | Q46362485 |
| | Analysis of sentinel lymph node positivity in patients with thin primary melanoma | Q46495695 |
| | Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma | Q46565593 |
| | Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients | Q46941511 |
| | Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma | Q46951033 |
| | Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? | Q47615560 |
| | Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. | Q47781508 |
| | Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma | Q47880534 |
| | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. | Q48411500 |
| | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). | Q48417717 |
| | Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma | Q48469829 |
| | American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture. | Q48517902 |
| | Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma | Q50489771 |
| | Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase | Q50511958 |
| | Population-based incidence of uveal melanoma in various races and ethnic groups | Q50770910 |
| | Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma | Q50935715 |
| | Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. | Q51002866 |
| | Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma | Q51012672 |
| | Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival | Q51124070 |
| | Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma | Q51787742 |
| | Variates of survival in metastatic uveal melanoma | Q51834538 |
| | Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study | Q53261505 |
| | A genome-based strategy uncovers frequent BRAF mutations in melanoma | Q53388101 |
| | Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial | Q53473469 |
| | F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. | Q53481364 |
| | Sentinel lymph node biopsy: A new perspective in head and neck mucosal melanoma? | Q53518414 |
| | Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study | Q53587515 |
| | Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort | Q54357561 |
| | Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma | Q54429549 |
| | Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 |
| | Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement | Q56908957 |
| | Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia | Q57226549 |
| | Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence | Q57569597 |
| | Histopathologic characteristics of uveal melanomas in eyes enucleated from the collaborative ocular melanoma study COMS report no. 6 | Q57619765 |
| | Sentinel Node Biopsy in Thin and Thick Melanoma | Q59489494 |
| | Radiotherapy after surgical resection for head and neck mucosal melanoma. | Q64915450 |
| | A clinicopathological study of 30 melanomas of the vulva | Q68011921 |
| | A phase II trial of taxol in metastatic melanoma | Q68087518 |
| | A phase II study of taxol in patients with malignant melanoma | Q68298891 |
| | "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness | Q71293134 |
| | The classification of malignant melanoma | Q71500917 |
| | Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 | Q72275233 |
| | Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center | Q73102827 |
| | Vertical growth phase and positive sentinel node in thin melanoma | Q73135038 |
| | Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma | Q73181804 |
| | Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system | Q73322618 |
| | Pretreatment factors predicting quality of life after treatment for head and neck cancer | Q73912410 |
| | The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18 | Q74184049 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 322 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition) | |
| P478 | volume | 3 | |